Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., … O’Shaughnessy, J. (2016). breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Annals of Oncology, 27, vi553. https://doi.org/10.1093/annonc/mdw435.03

Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).” Annals of Oncology 27 (October 1, 2016): vi553. https://doi.org/10.1093/annonc/mdw435.03.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Annals of Oncology. 2016 Oct 1;27:vi553.

Hortobagyi, G. N., et al. “breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).” Annals of Oncology, vol. 27, Oct. 2016, p. vi553. Scopus, doi:10.1093/annonc/mdw435.03.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell K, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron D, Xuan F, Souami F, Miller M, Germa C, O’Shaughnessy J. breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Annals of Oncology. 2016 Oct 1;27:vi553.